Elena Nikulina

Agenus brings long term survivor data on BOT plus BAL to SITC2026

Agenus brings long term survivor data on BOT plus BAL to SITC2026
Agenus to share cancer research

Agenus announced plans to present new research findings on its BOT plus BAL therapy for colorectal cancer at the SITC2026 conference. The presentation will include long term survivor data in refractory MSS metastatic colorectal cancer, as well as translational research evaluating the combination of BOT plus BAL with agenT-797.

The update signals continued progress in Agenus's oncology pipeline and offers further insight into its approach to treatment-resistant forms of cancer.

Agenus previously shared new details on the execution of the ROBBIN Phase 3 trial and its BOT+BAL immunotherapy strategy in colorectal cancer, as reported in an earlier update. The company has focused its research on treatment-resistant forms of the disease. These continued disclosures outline the evolving profile of its oncology programs.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.